ReviewJournal of cellular and molecular medicine2010
Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
Review in Journal of cellular and molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Influence of lanreotide on uptake ofEuropean journal of nuclear medicine and molecular imaging · 2019Trial
- Role of somatostatin receptor 2 (SSTR2) in pituitary adenomas.Clinical and translational medicine · 2025Article
- Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours.Endocrine oncology (Bristol, England) · 2025Article
- Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist.ACS medicinal chemistry letters · 2023Article
- Sleep Disturbance and Alzheimer's Disease: The Glial Connection.Neurochemical research · 2022Review
- Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.Endocrine pathology · 2021Review
- Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Expression of Somatostatin Receptor Subtypes (SSTR-1-SSTR-5) in Pediatric Hematological and Oncological Disorders.Molecules (Basel, Switzerland) · 2020Article
- Regulation of Somatostatin Receptor 2 Trafficking by C-Tail Motifs and the Retromer.Endocrinology · 2019Article
- Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.Drugs · 2019Review
- The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.PloS one · 2017Article
- Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver.Wiener klinische Wochenschrift · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.